Neil Bailey, Director of Clinical Oncology Research at Swedish, shared a post on LinkedIn:
“What happens when a medication for treating advanced pancreatic cancer that is widely regarded by oncologists and researchers as unprecedented in its results, but is not yet approved for commercial distribution? The Daraxonrasib expanded access progam (EAP) is a pathway for patients to recieve the medication without enrolling to a normal clinical trial and the Providence – Swedish Cancer Institute just dosed our first patient on the daraxonrasib EAP today.
This moment was made possible by the teamwork of our physicians, investigational pharmacy, regulatory, and study teams to bring options to patients who otherwise have nothing. Seeing the team overcome hurdles to bring these novel treatments to our patients is what makes working in research rewarding.”
You can also read: Daraxonrasib (RMC-6236): Clinical Development of a RAS(ON) Inhibitor Advancing Precision Therapy in RAS-Driven Solid Tumors
